In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

Leak Detection for Finished Sterile Containers
Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Aptar Pharma discusses how digital solutions improve patient outcomes
Webinars, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation, Market Insights

Ensuring Functional Performance and Regulatory Compliance of Elastomer Stoppers for M...
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

COVID 19: Drug Delivery Options to Succeed Sooner
Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions